Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review

Rodrigues, Larissa Alencar; Caroba, Mariana Emanuele Silva; Taba, Fernando Kengy; Filev, Renato; Gallassi, Andréa Donatti

doi:10.1016/j.pbb.2020.172982

Cited by 20 publications

(10 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature provides evidence supporting CBD’s therapeutic utility in the treatment of neuropathic pain, epilepsy, inflammation, bacterial infections, nausea, loss of appetite and sleeplessness [ 12 , 13 , 14 , 15 ]. CBD has been also shown to be effective for neuropsychiatric disorders including substance use disorders (SUDs) [ 16 , 17 , 18 , 19 , 20 ]. There is a number of articles that have reviewed recent research regarding CBD actions against psychostimulants [ 17 , 20 ], opioids [ 21 , 22 ], ∆ 9 -THC [ 23 ] and alcohol [ 24 , 25 ] in both humans and experimental animals.…”

Section: The History Of Medicinal Cannabidiolmentioning

confidence: 99%

“…CBD has been also shown to be effective for neuropsychiatric disorders including substance use disorders (SUDs) [ 16 , 17 , 18 , 19 , 20 ]. There is a number of articles that have reviewed recent research regarding CBD actions against psychostimulants [ 17 , 20 ], opioids [ 21 , 22 ], ∆ 9 -THC [ 23 ] and alcohol [ 24 , 25 ] in both humans and experimental animals. However, the majority of them focus on experimental evidence supporting or refuting the use of CBD for the treatment of SUDs, while little attention has been given to recent research regarding the possible receptor mechanisms underlying CBD’s action in different animal models of drug abuse and addiction.…”

Section: The History Of Medicinal Cannabidiolmentioning

confidence: 99%

See 1 more Smart Citation

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

Galaj

2020

IJMS

View full text Add to dashboard Cite

Substance use disorder (SUD) is a serious public health problem worldwide for which available treatments show limited effectiveness. Since the legalization of cannabis and the approval of cannabidiol (CBD) by the US Food and Drug Administration, therapeutic potential of CBD for the treatment of SUDs and other diseases has been widely explored. In this mini-review article, we first review the history and evidence supporting CBD as a potential pharmacotherapeutic. We then focus on recent progress in preclinical research regarding the pharmacological efficacy of CBD and the underlying receptor mechanisms on addictive-like behavior. Growing evidence indicates that CBD has therapeutic potential in reducing drug reward, as assessed in intravenous drug self-administration, conditioned place preference and intracranial brain-stimulation reward paradigms. In addition, CBD is effective in reducing relapse in experimental animals. Both in vivo and in vitro receptor mechanism studies indicate that CBD may act as a negative allosteric modulator of type 1 cannabinoid (CB1) receptor and an agonist of type 2 cannabinoid (CB2), transient receptor potential vanilloid 1 (TRPV1), and serotonin 5-HT1A receptors. Through these multiple-receptor mechanisms, CBD is believed to modulate brain dopamine in response to drugs of abuse, leading to attenuation of drug-taking and drug-seeking behavior. While these findings suggest that CBD is a promising therapeutic candidate, further investigation is required to verify its safety, pharmacological efficacy and the underlying receptor mechanisms in both experimental animals and humans.

show abstract

Section: The History Of Medicinal Cannabidiolmentioning

confidence: 99%

Section: The History Of Medicinal Cannabidiolmentioning

confidence: 99%

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

Galaj

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…While data on some outcomes are mixed and/or substance-specific, recent systematic review data from preclinical and human research indicate that the therapeutic provision of CBD may selectively reverse psycho-stimulant-related toxicity and seizures, behavioural sensitization, motivation to self-administer cocaine and methamphetamine, contextand stress-induced reinstatement of drug seeking behaviours. CBD may also potentiate the extinction and impaired the reinstatement of select psycho-stimulantinduced conditioned place preference (CPP) [112,113]. While a recent double-blind treatment study of the effects of CBD on crack-cocaine related craving did not find significant effects, longitudinal data from a Vancouver cohort of persons involved with illicit drug use (2012-2015) found that intentional cannabis use was associated with significant reductions in the frequency of crack-cocaine use [114,115].…”

Section: Implications For Interventionsmentioning

confidence: 99%

‘Resurgent’, ‘twin’ or ‘silent’ epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America

Fischer

O’Keefe-Markman

Lee

et al. 2021

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

In the early 2000s, increasing prevalence of psycho-stimulant (e.g., crack/cocaine, methamphetamine) use and related harms, including severe adverse health outcomes, was observed among - mostly marginalized - populations of persons using illicit drugs in North America, underscoring an urgent need for interventions options towards improved prevention and treatment. By about 2010, however, the ‘opioid crisis’, featuring unprecedented use and public health burden, had accelerated into full force in North America, largely muting attention to the psycho-stimulant issue until recently. Recent surveillance data on drug use and related mortality/morbidity from the present decade has documented a marked resurgence of psycho-stimulant use and harms especially in at-risk populations, commonly in direct combination with opioids, across North America, resulting in a ‘twin epidemic’ comprised of opioids and psycho-stimulants We briefly review select epidemiological data indicators for these developments from the United States and Canada; in the latter jurisdiction, related evidence has been less prevalent and systematic but corroborating the same trends. Evidently, the (widely ongoing) focus on the ‘opioid epidemic’ as a ‘mono-type’ drug problem has become an anachronism that requires urgent and appropriate correction. We then briefly consider existing, evidence-based options for – prevention and treatment – interventions targeting psycho-stimulant use and harms, which are substantially more limited and/or less efficacious than those available for problematic opioid use, while presenting major gaps and challenges. The observed resurgence of psycho-stimulants may, indirectly, relate to recent efforts towards curtailing (medical) opioid availability, thereby accelerating demand and supply for both illicit opioids and psycho-stimulants. The presently unfolding ‘twin epidemic’ of opioids and psycho-stimulants, combined with limited intervention resources, presents an acute challenge for public health and may crucially undermine actively extensive efforts to reduce opioid-related health harms in North America.

show abstract

“…In the last years, cannabidiol (CBD) has emerged as a new potential treatment for drug abuse (Chye et al, 2019), including cocaine (Calpe-López et al, 2019;Rodrigues et al, 2020). CBD's multi-target nature (Izzo et al, 2009) seems to contribute to its effectiveness in treating different psychiatric disorders, such as drug addiction.…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in mice

Alegre-Zurano

Luján

Cantacorps

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and PurposeTo remain abstinent represents one of the major challenges for the treatment of cocaine use disorder. Cocaine seeking elicited by drug-associated cues progressively intensifies during abstinence in a process termed incubation of craving, representing an aggravating factor for relapse. Cannabidiol is a phytocannabinoid that exerts protecting effects upon cocaine-seeking behaviour, although its effects on cocaine-craving incubation have never been elucidated.Experimental ApproachWe developed a mouse model of behavioural economic analysis of demand curves and incubation of cue-induced cocaine craving. Changes in the protein expression of AMPAR subunits and ERK1/2 phosphorylation were analysed. We also assessed the effects of cannabidiol (20 mg·kg-1) administered either during acquisition of cocaine self-administration or abstinence.Key ResultsMice efficiently performed the demand task and incubation of cocaine craving. Besides, changes in GluA1 and GluA2 protein levels were found along the abstinence in prelimbic cortex, ventral striatum and amygdala, as well as a decrease in ERK1/2 phosphorylation in ventral striatum. Cannabidiol reduced ongoing cocaine intake when administered during the acquisition phase of the self-administration, but failed to alter the subsequent demand task performance and incubation of cocaine craving. No effects were found when cannabidiol was administered during the abstinence period.Conclusion and ImplicationsWe provide here a novel model of behavioural economic analysis of demand curves and cue-induced incubation of cocaine-seeking behaviour for mice. Moreover, we show that cannabidiol exerts differential effects on the current model depending on the self-administration phase in which it was administered.What is already knownBehavioural economics and incubation of cocaine craving are well-stablished paradigms to evaluate cocaine seeking in rats.CBD reduces cocaine-seeking and cocaine-taking behaviours.What this study addsA mouse model of behavioural economic analysis of demand curves and incubation of cue-induced cocaine craving.CBD reduces cocaine self-administration and has no effect over demand task and cocaine-craving incubation.Clinical significanceA new behavioural model for studying cocaine addiction in mice.CBD exerts differential effects depending on when it was administered in the addictive process.Tables of Links

show abstract

Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review

Cited by 20 publications

References 75 publications

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

‘Resurgent’, ‘twin’ or ‘silent’ epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America

Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in mice

Contact Info

Product

Resources

About